BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Cepheid Delivers Xpert® Hemorrhagic Fever Panel Tests to Africa to Address Diagnostic Gaps in Ebola Bundibugyo Outbreak

  June 12, 2026

   · 

  5 min read
• Press Releases

  BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

  June 12, 2026

   · 

  12 min read
• 

  Business

  Novo hit with cybersecurity breach, urges vigilance among trial participants

  Novo Nordisk said that the information affected by the breach shouldn’t allow third parties to “identify participants in our clinical trials” despite “unauthorized access” to patients’ personal data.

  June 12, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Neurodegenerative disease

  Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

  The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

  June 12, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Amgen shores up Tavneos’ FDA defense with Duke data analysis

  After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.

  June 12, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

  June 12, 2026

   · 

  7 min read
• Press Releases

  MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

  June 12, 2026

   · 

  11 min read
• Press Releases

  BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

  June 12, 2026

   · 

  11 min read
• Press Releases

  Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

  June 12, 2026

   · 

  4 min read
• Press Releases

  CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

  June 12, 2026

   · 

  1 min read